Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OMEGA HEALTHCARE INVESTORS INCOHI · Entity 3362 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OMEGA HEALTHCARE INVESTORS INC
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,931 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 3,778 · Balance 47,931 F1: Represents Director compensation granted on June 5, 2026 via a Restricted Stock Grant Award Agreement which will vest on the date of the Company's 2027 Annual Meeting of Shareholders, which is approximately one (1) year from the date of the grant and will convert to common stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Director compensation granted on June 5, 2026 via a Restricted Stock Grant Award Agreement which will vest on the date of the Company's 2027 Annual Meeting of Shareholders, which is approximately one (1) year from the date of the grant and will convert to common stock on a one-for-one basis.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMICUS THERAPEUTICS, INC.
Report date April 27, 2026 · Filed April 27, 2026
Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 1
1 source rowRow 1 · 2026-04-27 · Disposition to issuer · Disposed 118,598 · Balance 0 F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 98,184 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger). |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2029-06-27 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-27 · Disposition to issuer · Disposed 25,964 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.81 · Expires 2030-06-04 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-27 · Disposition to issuer · Disposed 18,574 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-27 · Disposition to issuer · Disposed 36,111 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2032-06-09 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-27 · Disposition to issuer · Disposed 45,423 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-27 · Disposition to issuer · Disposed 30,474 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-27 · Disposition to issuer · Disposed 42,467 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2035-06-05 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-27 · Disposition to issuer · Disposed 74,872 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4: Each Option vested in full in connection with consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 98,184 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
F3: Each Option was fully vested.
F4: Each Option vested in full in connection with consummation of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2020 Filed Sep 1, 2020 17:26 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 500 | $30.60 | $15,300.00 |
DisclosureSEC source: 0001127602-20-024521 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,085 F1 · shares: This transaction was executed at an average weighted price of $30.60, with all trades within a dollar of the average. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, Omega Healthcare Investors, full information regarding the number of shares and prices at which the the transaction was effected. This trade was executed pursuant to a 10b5-1 trading plan. Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 20:28 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $14.62 | $21,930.00 |
DisclosureSEC source: 0001209191-20-049134 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,967 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 13:28 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 500 | $31.80 | $15,900.00 |
DisclosureSEC source: 0001127602-20-022780 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,585 F1 · shares: This transaction was executed at an average weighted price of $31.80, with all trades within a dollar of the average. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, Omega Healthcare Investors, full information regarding the number of shares and prices at which the the transaction was effected. This trade was executed pursuant to a 10b5-1 trading plan. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:05 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $14.53 | $21,795.00 |
DisclosureSEC source: 0001209191-20-045084 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,467 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 17:41 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 500 | $29.86 | $14,930.00 |
DisclosureSEC source: 0001127602-20-020762 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,085 F1 · shares: This transaction was executed at an average weighted price of $29.86, with all trades within a dollar of the average. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, Omega Healthcare Investors, full information regarding the number of shares and prices at which the the transaction was effected. This trade was executed pursuant to a 10b5-1 trading plan. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 23:38 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $15.20 | $22,800.00 |
DisclosureSEC source: 0001104659-20-081466 · a4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,967 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 18:24 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | GrantCommon Stock | 4,597 | $32.63 | $150,000.11 |
DisclosureSEC source: 0001127602-20-019549 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,585 F1 · shares: Represents Director compensation via the annual grant of restricted stock that will vest on the date of the Company's 2021 Annual Meeting of shareholders, which is approximately one year from grant date. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:51 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 18,574 | $0.00 Strike: $12.81 | $0.00 |
DisclosureSEC source: 0001209191-20-035000 · doc4.xml · derivative · entry 2 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,574 Underlying: Common Stock · 18,574 shares Expires 2030-06-04 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:51 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 5,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035000 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,467 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 01:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 2,000 | $12.66 | $25,310.80 |
DisclosureSEC source: 0001209191-20-034324 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,612 Read SEC document |
| June 01, 2020 Filed Jun 1, 2020 18:46 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 800 | $31.73 | $25,384.00 |
DisclosureSEC source: 0001127602-20-018228 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,988 F1 · shares: This transaction was executed in a single block trade at $31.73. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 23:59 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 4,945 | $10.07 | $49,796.15 |
DisclosureSEC source: 0001209191-19-047572 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,612 Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 21:02 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 25,964 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039772 · doc4.xml · derivative · entry 2 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,964 Underlying: Common Stock · 25,964 shares Expires 2029-06-27 F2 · derivative.exercise_date: These stock options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the vesting commencement date and the remainder vesting ratably each month thereafter in equal installments over a three year period. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 21:02 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039772 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 F1 · shares: These restricted stock units (RSUs) vest in a series of installments over a four year period with 25% vesting each year upon the anniversary of the grant. Read SEC document |
| June 27, 2019 Filed Jun 18, 2020 00:30 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037468 · doc4a.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 F1 · security: Granted in the form of Restricted Stock Units ("RSUs") these RSUs vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter over a three year period. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 15:27 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | GrantCommon Stock | 4,138 | $36.25 | $150,002.50 |
DisclosureSEC source: 0001127602-19-021300 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,188 F1 · shares: Represents annual grant of Restricted Stock subject to time-based vesting. Read SEC document |
| February 14, 2019 Filed Feb 14, 2019 21:57 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 1,350 | $36.68 | $49,512.20 |
DisclosureSEC source: 0001127602-19-006030 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,050 Read SEC document |
| October 31, 2018 Filed Nov 6, 2018 00:13 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | GrantCommon Stock | 2,700 | $33.34 | $90,018.00 |
DisclosureSEC source: 0000950138-18-000592 · edgar.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,700 F1 · shares: Represents grant of restricted stock subject to time-based vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.